SI1608685T1 - Antagonisti VEGF za zdravljenje diabetesa - Google Patents

Antagonisti VEGF za zdravljenje diabetesa

Info

Publication number
SI1608685T1
SI1608685T1 SI200430312T SI200430312T SI1608685T1 SI 1608685 T1 SI1608685 T1 SI 1608685T1 SI 200430312 T SI200430312 T SI 200430312T SI 200430312 T SI200430312 T SI 200430312T SI 1608685 T1 SI1608685 T1 SI 1608685T1
Authority
SI
Slovenia
Prior art keywords
vegf
diabetes
treatment
vegf antagonists
blocking
Prior art date
Application number
SI200430312T
Other languages
English (en)
Inventor
Mark W Sleeman
Stanley J Wiegand
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of SI1608685T1 publication Critical patent/SI1608685T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
SI200430312T 2003-03-28 2004-03-26 Antagonisti VEGF za zdravljenje diabetesa SI1608685T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45879003P 2003-03-28 2003-03-28
EP04758372A EP1608685B1 (en) 2003-03-28 2004-03-26 Vegf antagonists for the treatment of diabetes
PCT/US2004/009246 WO2004087206A2 (en) 2003-03-28 2004-03-26 Methods of treating diabetes by blocking vegf-mediated activity

Publications (1)

Publication Number Publication Date
SI1608685T1 true SI1608685T1 (sl) 2007-08-31

Family

ID=33131825

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200430312T SI1608685T1 (sl) 2003-03-28 2004-03-26 Antagonisti VEGF za zdravljenje diabetesa

Country Status (17)

Country Link
US (1) US7052691B2 (sl)
EP (1) EP1608685B1 (sl)
JP (2) JP4730909B2 (sl)
AT (1) ATE354592T1 (sl)
AU (1) AU2004226417B2 (sl)
BR (1) BRPI0408749B1 (sl)
CA (1) CA2519787C (sl)
CY (1) CY1106530T1 (sl)
DE (1) DE602004004883T2 (sl)
DK (1) DK1608685T3 (sl)
ES (1) ES2278333T3 (sl)
HK (1) HK1080092A1 (sl)
MX (1) MXPA05008972A (sl)
PL (1) PL1608685T3 (sl)
PT (1) PT1608685E (sl)
SI (1) SI1608685T1 (sl)
WO (1) WO2004087206A2 (sl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007001241A (es) 2004-07-30 2007-07-11 Regeneron Pharma Metodos para tratar diabetes tipo i mediante el bloqueo de la actividad mediada de vegf.
ES2633574T3 (es) 2005-03-25 2017-09-22 Regeneron Pharmaceuticals, Inc. Formulaciones de antagonistas de VEGF
US7608261B2 (en) 2006-06-16 2009-10-27 Regeneron Pharmacuticals, Inc. VEGF antagonist formulations suitable for intravitreal administration
ES2345596B1 (es) * 2009-03-26 2011-07-13 Fundacion Progreso Y Salud Composicion para la prevencion o el tratamiento de la diabetes mellitus.
US20100330098A1 (en) * 2009-06-29 2010-12-30 Kuo Calvin J Methods to regulate glucose metabolism
MX349901B (es) 2011-01-13 2017-08-18 Regeneron Pharma Uso de un antagonista de factor de crecimiento endotelial vascular para tratar transtornos oculares angiogenicos.
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
ES2648809T3 (es) 2014-01-25 2018-01-08 Chengdu Kanghong Biotechnologies Co., Ltd. Proteína de fusión que inhibe la angiogénesis o el crecimiento y uso de esta
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
EA035674B1 (ru) 2014-07-18 2020-07-24 Санофи Способ определения того, является ли пациент, предположительно страдающий от рака, кандидатом для терапии афлиберцептом
RU2744860C2 (ru) 2015-12-30 2021-03-16 Кодиак Сайенсиз Инк. Антитела и их конъюгаты
ITUB20169928A1 (it) * 2016-01-12 2017-07-12 Medical And Biotechnological Services In Sigla M B S Srl Formulazioni farmaceutiche per il trattamento del diabete
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9410533D0 (en) * 1994-05-26 1994-07-13 Lynxvale Ltd In situ hybridisation and immuno-Chemical localisation of a growth factor
JP4926320B2 (ja) * 1999-04-28 2012-05-09 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム Ｖｅｇｆの選択的阻害による癌処置のための組成物および方法
US6833349B2 (en) 1999-06-08 2004-12-21 Regeneron Pharmaceuticals, Inc. Methods of treating inflammatory skin diseases
ME00024B (me) * 1999-06-08 2010-02-10 Regeneron Pharma Modifikovani himerni polipeptidi sa poboljšanim farmakokinetičkim osobinama

Also Published As

Publication number Publication date
WO2004087206A3 (en) 2004-12-16
CY1106530T1 (el) 2012-01-25
WO2004087206A2 (en) 2004-10-14
DK1608685T3 (da) 2007-06-11
JP2011037894A (ja) 2011-02-24
ATE354592T1 (de) 2007-03-15
CA2519787A1 (en) 2004-10-14
PL1608685T3 (pl) 2007-07-31
US7052691B2 (en) 2006-05-30
EP1608685A2 (en) 2005-12-28
EP1608685B1 (en) 2007-02-21
PT1608685E (pt) 2007-05-31
AU2004226417B2 (en) 2009-01-22
HK1080092A1 (en) 2006-04-21
AU2004226417A1 (en) 2004-10-14
BRPI0408749A (pt) 2006-03-28
DE602004004883T2 (de) 2007-11-15
BRPI0408749B1 (pt) 2016-10-04
MXPA05008972A (es) 2005-11-04
US20040213787A1 (en) 2004-10-28
ES2278333T3 (es) 2007-08-01
JP2006521397A (ja) 2006-09-21
DE602004004883D1 (de) 2007-04-05
JP4730909B2 (ja) 2011-07-20
CA2519787C (en) 2012-06-05

Similar Documents

Publication Publication Date Title
HK1080092A1 (en) Vegf antagonists for the treatment of diabetes
HK1105167A1 (en) Methods of treating type i diabetes by blocking vegf-mediated activity
DE60210093D1 (de) Beta-amino-tetrahydroimidazo(1,2-a)pyrazine und -tetrahydrotriazolo(4,3-a)pyrazine als dipeptidyl peptidase inhibitoren zur behandlung oder prevention von diabetes
AP1913A (en) Substituted benzazoles and use thereof as raf kinase inhibitors
MXPA05010819A (es) Uso de antagonistas de opioide perifericos, especialmente metilnaltrexona para tratar sindrome de intestino irritable.
WO2006023649A3 (en) Treatment of severe multiple sclerosis
MY169308A (en) Treatment of tnf? related disorders
WO2004105757A3 (en) Use of rho-kinase inhibitors in the treatment of aneurysm and cardiac hypertrophy
EA200801118A1 (ru) Способ ингибирования flt3 киназы
WO2005107726A3 (en) Method for the treatment of back pain
DE60133029D1 (de) Mittel zur prävention oder behandlung von psoriasi
TW200716673A (en) Use of TNF &ahr; inhibitor for treatment of erosive polyarthritis
WO2003105840A3 (en) SPHINGOSINE KINASE INHIBITORS
MX2007006204A (es) Combinaciones que comprenden inhibidores de jak y cuando menos uno de entre inhibidores de bcr-abl, flt-3, fak o raf cinasa.
WO2004084943A8 (en) Use of antagonists of ghrelin or ghrelin receptor to treat intestinal inflammation
EA200800755A1 (ru) Ikk ингибиторы, предназначенные для лечения эндометриоза
WO2007075852A3 (en) Calcium channel antagonists
ATE555803T1 (de) Verwendung von osteopontin zur behandlung und/oder vorbeugung von neurologischen erkrankungen
ATE520709T1 (de) Campylobacter-polypeptide und verwendungsverfahren
WO2006060787A3 (en) Delaying or preventing onset of multiple sclerosis
BRPI0718469A2 (pt) Uso de um antagonista de interleucina 1 (il-1), método para tratar, inibir, ou melhorar pseudogota, uso de um ou mais agentes terapêuticos, e, produto.
EA200800766A1 (ru) Ингибиторы pi3k для лечения эндометриоза
WO2003037310A3 (en) Use of inhibitors of the abc drug transporter to increase the activity of anti-microbial agents
WO2004009773A3 (en) Methods and compositions for activating or inhibiting vegf-d and vegf-c
WO2006016192A3 (en) Combination therapy with nk3 receptor antagonists for the treatment of schizophrenia